ASH Annual Meeting and Exposition | Conference

MK-1045 Therapy Proves Active, Safe With Dose Modification in Relapsed/Refractory ALL

December 9th 2025

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL

December 9th 2025

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma

December 9th 2025

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML

December 9th 2025

Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.

Tagraxofusp/Azacitidine/Venetoclax Triplet Is Safe, Feasible in First-Line and R/R BPDCN

December 8th 2025

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Sonrotoclax Displays Activity in BTK Inhibitor–Pretreated R/R MCL

December 8th 2025

Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.

MaaT013 Shows Tolerability, Early Efficacy in Refractory Acute GVHD With GI Involvement

December 8th 2025

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Ziftomenib Plus Venetoclax and Azacitidine Is Tolerable and Active in NPM1/KMT2A+ AML

December 8th 2025

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

Ziftomenib at RP2D Demonstrates High Response Rates for NPM1-Mutated AML

December 8th 2025

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma

December 8th 2025

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Talquetamab Plus Teclistamab Displays Activity in R/R Multiple Myeloma With True EMD

December 8th 2025

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Linvoseltamab Generates Responses in Newly Diagnosed Myeloma

December 8th 2025

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma

December 8th 2025

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

CAMMA 3 Data Support Ongoing Investigation of Cevostamab in Heavily Pretreated Myeloma

December 8th 2025

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

December 8th 2025

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

December 8th 2025

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.